Internal Medicine, Medical Oncology · Fairfax, VA
NPI
1902874514
Since 2006
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
8613 Lee Hwy # 200n
Fairfax, VA, 22031
Phone (032) 083-1557
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.1M
122,350 services
Medicare patients, 2024
1,073
Average age 75
Drug cost, 2024
$3.4M
491 prescriptions
Company payments, 2025
$111K
From 59 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Alexander I Spira was code J1439 (injection, ferric carboxymaltose, 1 mg), 18,825 times for 22 patients. In total Alexander I Spira billed 122,350 services in 191 codes, and Medicare paid $2.1M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-11-11.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 18,825 | 22 | $0.87 | $16K |
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 13,500 | 38 | $39.21 | $529K |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 6,360 | 16 | $2.20 | $14K |
| J0897 Injection, denosumab, 1 mg | Office | 4,020 | 25 | $20.37 | $82K |
| J9267 Injection, paclitaxel, 1 mg | Office | 3,330 | 12 | $0.08 | $275 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,127 | 85 | $0.09 | $192 |
| J1568 Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 1,990 | 14 | $36.87 | $73K |
| J9041 Injection, bortezomib, 0.1 mg | Office | 1,855 | 16 | $1.44 | $2,666 |
| 80053 Clinical Chemistry | Office | 1,052 | 369 | $10.23 | $11K |
| 85025 Blood Count | Office | 909 | 211 | $7.50 | $6,813 |
| 99213 Office E&M - Established | Office | 899 | 376 | $76.61 | $69K |
| J1626 Injection, granisetron hydrochloride, 100 mcg | Office | 752 | 40 | $0.26 | $194 |
| 96413 Chemotherapy Administration | Office | 629 | 187 | $117.59 | $74K |
| 99214 Office E&M - Established | Office | 533 | 239 | $106.12 | $57K |
| 96375 Injection Administration | Office | 452 | 118 | $13.78 | $6,228 |
By year: 2022 $2.3M for 130,899 services; 2023 $1.7M for 95,047 services; 2024 $2.1M for 122,350 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 80053 Clinical Chemistry | 1,052 | 369 | $10.23 | $11K |
| 85025 Blood Count | 909 | 211 | $7.50 | $6,813 |
| 36415 Venipuncture Blood Collection | 452 | 148 | $8.50 | $3,844 |
| 82378 Clinical Chemistry | 278 | 82 | $17.94 | $4,988 |
| 82784 Immunoassay | 251 | 46 | $9.11 | $2,287 |
| 83883 Clinical Chemistry | 168 | 42 | $13.33 | $2,239 |
| 83550 Clinical Chemistry | 139 | 109 | $8.57 | $1,191 |
| 82728 Clinical Chemistry | 139 | 109 | $13.36 | $1,857 |
| 83540 Clinical Chemistry | 139 | 109 | $6.34 | $881 |
| 84443 Clinical Chemistry | 103 | 50 | $16.46 | $1,695 |
Medicare prescription drug claims, 2024
In 2024, the drug Alexander I Spira prescribed most often to Medicare patients was Lorbrena (Lorlatinib), with 58 prescriptions and refills. In total Alexander I Spira wrote 491 Medicare prescriptions that cost $3.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Lorbrena Lorlatinib | 58 | 58 | Under 11 | $1.2M |
| Tagrisso Osimertinib Mesylate | 57 | 57 | Under 11 | $956K |
| Alecensa Alectinib Hcl | 39 | 39 | Under 11 | $738K |
| Eliquis Apixaban | 30 | 36 | Under 11 | $20K |
| Prednisone Generic | 23 | 25 | 12 | $97.18 |
| Spironolactone Generic | 16 | 22 | Under 11 | $79.61 |
| Prochlorperazine Maleate Generic | 16 | 16 | 15 | $213 |
| Dexamethasone Generic | 14 | 16 | Under 11 | $316 |
| Levothyroxine Sodium Generic | 12 | 16 | Under 11 | $151 |
| Alunbrig Brigatinib | 12 | 12 | Under 11 | $232K |
| Furosemide Generic | 11 | 13 | Under 11 | $42.74 |
Brand drugs: 238 claims; generic drugs: 253 claims; opioid claims: 18.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Alexander I Spira $111K ($107K in general payments such as food, travel and fees and $4,378 for research) from 59 companies. The largest payer was Janssen Biotech, Inc. with $21K.
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. JNJ | 7 | $21K |
| Merck Healthcare KGaA | 5 | $16K |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 14 | $13K |
| Janssen Global Services, LLC JNJ | 2 | $8,063 |
| Janssen Scientific Affairs, LLC JNJ | 3 | $7,275 |
| Eli Lilly and Company LLY | 7 | $6,751 |
| EMD Serono Research & Development Institute, Inc. MRK.DE | 1 | $6,043 |
| Boehringer Ingelheim International GmbH | 3 | $5,381 |
| GlaxoSmithKline, LLC. GSK | 4 | $4,838 |
| EMD Serono, Inc. MRK.DE | 1 | $3,450 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.